Effects of Dalfampridine on Cognition in Multiple Sclerosis
Phase of Trial: Phase II/III
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Fampridine (Primary)
- Indications Cognition disorders; Multiple sclerosis
- Focus Therapeutic Use
- 12 Apr 2016 Status changed from recruiting to completed.
- 07 Jan 2016 Planned End Date changed from 1 Apr 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
- 07 Jan 2016 Planned primary completion date changed from 1 Apr 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.